AIM ImmunoTech Inc (AIM)

Form DEF 14A - Other definitive proxy statements

Form 424B3 - Prospectus [Rule 424(b)(3)]

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

OCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the...

Form EFFECT - Notice of Effectiveness

AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series

OCALA, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the...

Form 424B3 - Prospectus [Rule 424(b)(3)]

AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer

OCALA, Fla., June 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the...

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form EFFECT - Notice of Effectiveness

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

OCALA, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM,” or the...

Form 8-K - Current report

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]